1.115  -0.015 (-1.33%)		12-08 16:00
Open: 1.13 High: 1.21 Volume: 255,509		Pre. Close: 1.13 Low: 1.07 Market Cap: 23(M)

Short term
Mid term
Targets	6-month :	2.9	1-year :	3.96
Resists	First :	2.48	Second :	3.39
Pivot price	1.17
Supports	First :	1.02	Second :	0.85
MAs	MA(5) :	1.22	MA(20) :	1.23
	MA(100) :	2.74	MA(250) :	4.64
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	11.1	D(3) :	20.3
RSI	RSI(14): 37.9
52-week	High :	8.21	Low :	1.02

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MYNZ ] has closed above bottom band by 37.6%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.21 - 1.22	1.22 - 1.22
Low:	1.05 - 1.06	1.06 - 1.07
Close:	1.1 - 1.11	1.11 - 1.12

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Wed, 06 Dec 2023
Mainz Biomeds ColoAlert A Groundbreaking Advancement in Colorectal Cancer Diagnostics - Best Stocks

Tue, 05 Dec 2023
Mainz Biomed Unveils Groundbreaking Findings on Enhanced ColoAlert for Colorectal Cancer Detection - Best Stocks

Mon, 27 Nov 2023
Where Will Mainz Biomed NV (MYNZ) Stock Go Next After It Is Down 5.79% in a Week? - InvestorsObserver

Fri, 24 Nov 2023
Mainz Biomed NV (MYNZ) Stock Falls -0.87% This Week; Should You Buy? - InvestorsObserver

Thu, 23 Nov 2023
FY2023 EPS Estimates for Mainz Biomed (NASDAQ:MYNZ) Raised by HC Wainwright - Defense World

Tue, 21 Nov 2023
Ceapro (OTCMKTS:CRPOF) and Mainz Biomed (NASDAQ:MYNZ) Critical Analysis - Defense World

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Diagnostics & Research
Shares Out	0 (M)
Shares Float	20 (M)
Held by Insiders	1.478e+007 (%)
Held by Institutions	23.7 (%)
Shares Short	110 (K)
Shares Short P.Month	0 (K)

EPS	-2.819e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	104.9 %
Return on Equity (ttm)	-93.5 %
Qtrly Rev. Growth	874000 %
Gross Profit (p.s.)	127.1
Sales Per Share	-484.06
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-22 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	3.66

Dividend	0
Forward Dividend	138550
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.